Tumor Necrosis Factor-α, human (hTNF-α)
ROCHE/11088939001 - recombinant (yeast)
Synonym: hTNF; human necrosis factor
Product Type: Chemical
TNF alpha Pathway Research areas: Apoptosis, Inflammation and Infection, Cancer biology, Immunology, Developmental biology Disease areas: Autoimmune disorders, cancer, cardiomyopathy, HIV, hepatitis, tuberculosis, ulcerative colitis See also: T6674; T0157; T7539; 11371843001; SRP8024; 11088939001
Apoptosis Pathway Research areas: Apoptosis, Inflammation and Infection, Cancer biology, Immunology, Developmental biology Disease areas: Autoimmune disorders, cancer, cardiomyopathy, HIV, hepatitis, tuberculosis, ulcerative colitis See also: T6674; T0157; T7539; 11371843001; SRP8024; 11088939001
| assay | ≥95% (SDS-PAGE) |
| biological source | human |
| form | solution |
| impurities | <0.1 EU/μgtested (LAL test) |
| manufacturer/tradename | Roche |
| mol wt | 17,000 Da |
| packaging | pkg of 1,000,000 U (10 μg, 1ml) |
| potency | ≤0.01 ng/mL EC50 |
| Quality Level | 100  |
| recombinant | expressed in yeast |
| specific activity | >1*10^8 U/mg |
| storage condition | avoid repeated freeze/thaw cycles |
| storage temp. | −20°C |
| UniProt accession no. | Q9UBM5  |
| Analysis Note: | Purity: >95% (SDS-PAGE) Endotoxin level: <0.1 EU/μg (LAL-test), <10 EU/ml (LAL-test) |
| Application: | Tumor Necrosis Factor-α (hTNF-α) • Shows cytolytic and/or cytostatic activity on a variety of transformed cell lines. • Has activating and growth stimulating activities on a variety of normal cells. • Has antiviral activity on many cell types in vitro. • Can cause tumor necrosis of certain tumors in vivo. |
| Biochem/physiol Actions: | Human hTNF-α is effective on human and mouse cells. |
| Biochem/physiol Actions: | Receptor p55 and p75, belonging to the TNFR gene family, mediate the biological activity of TNF-a, and are co-expressed on the surface of various cell types. The pleiotropic action of TNF-a is initiated by binding to either of the two receptors. |
| Biochem/physiol Actions: | Species specificity: human, mouse |
| General description: | >1 x 10⊥8 U/mg, <0.01 ng/ml (hTNF-a, NIBSC, interim standard, 87/650), at least the same specific activity (EC50) compared to the indicated standard is guaranteed. |
| Other Notes: | Chain Length 157 AA |
| Other Notes: | EC50 definition: The amount of hTNF-α that is required to mediate half-maximal cytotoxicity (MTT cleavage) with WEHI 164 cells in the presence of actinomycin D (1 unit equals ≤0.01 ng/ml). |
| Other Notes: | For life science research only. Not for use in diagnostic procedures. 1 EU corresponds to 0.1 ng |
| Other Notes: | One polypeptide chain (157 amino acids), identical to natural hTNF-α. |
| Physical form: | Solution, filtered through 0.2 μm pore size membrane. |
| Preparation Note: | Working concentration: 1 ng/ml For complete cell lysis of sensitive cell lines about 1 ng/ml is recommended. Working solution: Dilute the concentrated hTNF-α solution (10 μg/ml) with PBS or culture medium containing BSA (or HSA), 1 mg/ml (0.1%) or serum 1 to 10%. Storage conditions (working solution): -15 to -25 °C It is recommended to store the solution in aliquots at -15 to -25 °C. Note: Avoid repeated freezing and thawing. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | nwg |
| Flash Point(F) | does not flash |
| Flash Point(C) | does not flash |
| Purity | ≥95% (SDS-PAGE) |
| activity | specific activity: >1*10^8 U/mg |
| Storage Temp. | −20°C |
| UNSPSC | 12352207 |